NEW ORLEANS, July 22, 2025 /PRNewswire/ -- Answer ALS is proud to announce the launch of a groundbreaking collaborative initiative aimed at accelerating AI-powered drug discovery for ALS and other ...

Sept 16 (Reuters) - Novartis has halted development of an experimental drug for amyotrophic lateral sclerosis after it failed to ‌meet goals in a mid-stage study, marking the latest disappointment ...

The US Food and Drug Administration (FDA) on Monday finalized guidance to assist in the clinical development of treatments for amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease.

After decades of hard-won progress, ALS drug development is entering a new era, building on established efficacy measures like survival and ALSFRS-R with biology-driven science that captures the full ...

Cambridge, Mass., July 02, 2025 (GLOBE NEWSWIRE) -- A team of researchers from the MIT Sloan School of Management, the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital (MGH), ...

After a period of clinical recalibration, the ALS and FTD field is regaining momentum, driven by a deeper biological understanding, more refined translational strategies, and continued industry ...

Acting US Food and Drug Administration (FDA) Commissioner Ned Sharpless on Thursday announced that the agency would finalize guidance on developing treatments for amyotrophic lateral sclerosis (ALS) ...

Pennington Biomedical’s Dr. Jeff Keller and Dr. Aron Culotta of Tulane to lead collaboration of AI researchers, neuroscientist and drug developers Answer ALS is proud to announce the launch of a ...